Patents Assigned to Tel-Aviv University Future Technology Development L.P.
-
Patent number: 7446092Abstract: Novel conjugates that are capable of inhibiting GSK-3 activity, a process of producing same, pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions are disclosed. Methods of treating affective disorders using GSK-3 inhibitors are further disclosed.Type: GrantFiled: December 11, 2003Date of Patent: November 4, 2008Assignee: Tel Aviv University Future Technology Development L.P.Inventor: Hagit Eldar-Finkelman
-
Patent number: 7413824Abstract: The present invention provides improved, low-cost fuel cells having reduced fuel crossover, reduced sensitivity to metal ion impurities and ability to operate under a broad range of temperatures. The invention further provides improved methods for catalyst preparation and a new integrated flow field system for use in H2/O2 fuel cells.Type: GrantFiled: January 18, 2001Date of Patent: August 19, 2008Assignee: Tel Aviv University Future Technology Development L.P.Inventors: Emanuel Peled, Tair Duvdevani, Avi Melman, Adi Aharon
-
Patent number: 7378432Abstract: Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions.Type: GrantFiled: November 17, 2005Date of Patent: May 27, 2008Assignee: Tel Aviv University Future Technology Development L.P.Inventors: Hagit Eldar-Finkelman, Moshe Portnoy
-
Patent number: 7348308Abstract: Peptide inhibitors of glycogen synthase kinase-3 (GSK-3) having an amino acid sequence motif of XZXXXS(p)X, wherein S(p)=phosphorylated serine or phosphorylated threonine, X=any amino acid, and Z=any amino acid except serine or threonine. These inhibitors, which are about 7 to 20 amino acids long, are specific for GSK-3 and strongly inhibit the enzyme with an IC50 of about 150 ?M. Also provided are methods of treating biological conditions mediated by GSK-3 activity, such as potentiating insulin signaling in a subject, treating or preventing type 2 diabetes in a patient, and treating Alzheimer's Disease by administering peptide inhibitors. Compositions of these peptide inhibitors and pharmaceutically acceptable carriers are also provided, as is a method for identifying inhibitors of GSK-3. The invention further relates to a computer-assisted method of structure based drug design of GSK-3 inhibitors using a three-dimensional structure of a peptide substrate of GSK-3.Type: GrantFiled: November 21, 2006Date of Patent: March 25, 2008Assignee: Tel Aviv University Future Technology Development L.P.Inventor: Hagit Eldar-Finkelman
-
Publication number: 20070135334Abstract: A peptide comprising at least 5 amino acid residues.and less than 15 amino acid residues, the peptide including an amino acid sequence as set forth in SEQ ID NO: 7 as well as pharmaceutical compositions, kits and methods for diagnosing and treating amyloid associated diseases.Type: ApplicationFiled: January 23, 2007Publication date: June 14, 2007Applicant: Tel Aviv University Future Technology Development L.P.Inventor: Ehud Gazit
-
Publication number: 20070072791Abstract: Peptide inhibitors of glycogen synthase kinase-3 (GSK-3) having an amino acid sequence motif of XZXXXS(p)X, wherein S(p)=phosphorylated serine or phosphorylated threonine, X=any amino acid, and Z=any amino acid except serine or threonine. These inhibitors, which are about 7 to 20 amino acids long, are specific for GSK-3 and strongly inhibit the enzyme with an IC50 of about 150 ?M. Also provided are methods of treating biological conditions mediated by GSK-3 activity, such as potentiating insulin signaling in a subject, treating or preventing type 2 diabetes in a patient, and treating Alzheimer's Disease by administering peptide inhibitors. Compositions of these peptide inhibitors and pharmaceutically acceptable carriers are also provided, as is a method for identifying inhibitors of GSK-3. The invention further relates to a computer-assisted method of structure based drug design of GSK-3 inhibitors using a three-dimensional structure of a peptide substrate of GSK-3.Type: ApplicationFiled: November 21, 2006Publication date: March 29, 2007Applicant: Tel Aviv University Future Technology Development L.P.Inventor: Hagit Eldar-Finkelman
-
Patent number: 7157422Abstract: Peptide inhibitors of glycogen synthase kinase-3 (GSK-3) having an amino acid sequence motif of XZXXXS(p)X, wherein S(p)=phosphorylated serine or phosphorylated threonine, X=any amino acid, and Z=any amino acid except serine or threonine. These inhibitors, which are about 7 to 20 amino acids long, are specific for GSK-3 and strongly inhibit the enzyme with an IC50 of about 150 ?M. Also provided are methods of treating biological conditions mediated by GSK-3 activity, such as potentiating insulin signaling in a subject, treating or preventing type 2 diabetes in a patient, and treating Alzheimer's Disease by administering peptide inhibitors. Compositions of these peptide inhibitors and pharmaceutically acceptable carriers are also provided, as is a method for identifying inhibitors of GSK-3. The invention further relates to a computer-assisted method of structure based drug design of GSK-3 inhibitors using a three-dimensional structure of a peptide substrate of GSK-3.Type: GrantFiled: March 29, 2004Date of Patent: January 2, 2007Assignee: Tel Aviv University Future Technology Development L.P.Inventor: Hagit Eldar-Finkelman
-
Publication number: 20060234947Abstract: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.Type: ApplicationFiled: June 21, 2006Publication date: October 19, 2006Applicant: Tel Aviv University Future Technology Development L.PInventor: Ehud Gazit
-
Patent number: 7096061Abstract: A method is described for generating an impedance image of the chest, in which electrical data of the chest is acquired, and a finite volume method is used to calculate an impedance image from the electrical data, using an analytical expression for the Jacobian.Type: GrantFiled: July 3, 2002Date of Patent: August 22, 2006Assignee: Tel-Aviv University Future Technology Development L.P.Inventor: Shimon Arad
-
Publication number: 20060064029Abstract: A method of determining an impedance of at least one lung of a patient having an implanted pacemaker that comprises first and second leads and a case, the method comprising: a) using the leads and the case to acquire at least a first and a second impedance measurement responsive to impedance of the patient's chest that are at least partially independent; and b) using the impedance measurements to determine the impedance of at least one of the lungs substantially independently of impedance of the other lung.Type: ApplicationFiled: September 13, 2005Publication date: March 23, 2006Applicant: Tel-Aviv University Future Technology Development L.P.Inventor: Shimon Arad (Abboud)
-
Publication number: 20050107719Abstract: A method of estimating stroke volume of the heart, comprising: taking a first set of electrical data of the chest at a first phase of the cardiac cycle; estimating a first volume of the heart from the first set of electrical data; taking a second set of electrical data of the chest at a second phase of the cardiac cycle; estimating a second volume of the heart from the second set of electrical data; and using the difference between the first and second volumes of the heart to estimate the stroke volume of the heart.Type: ApplicationFiled: December 27, 2004Publication date: May 19, 2005Applicant: Tel-Aviv University Future Technology Development L.P.Inventor: Shimon Arad (Abbound)
-
Patent number: 6811911Abstract: The present invention provides an ion conducting matrix comprising: (i) 5 to 60% by volume of an inorganic powder having a good aqueous electrolyte absorption capacity; (ii) 5 to 50% by volume of a polymeric binder that is chemically compatible with an aqueous electrolyte; and (iii) 10 to 90% by volume of an aqueous electrolyte, wherein the inorganic powder comprises essentially sub-micron particles. The present invention further provides a membrane being a film made of the matrix of the invention and a composite electrode comprising 10 to 70% by volume of the matrix of the invention.Type: GrantFiled: October 18, 2000Date of Patent: November 2, 2004Assignee: Tel Aviv University Future Technology Development L.P.Inventors: Emanuel Peled, Tair Duvdevani, Avi Melman
-
Patent number: 6780625Abstract: Peptide inhibitors of glycogen synthase kinase-3 (GSK-3) have an amino acid sequence motif of XZXXXS(p)X, wherein S(p)=phosphorylated serine or phosphorylated threonine, X=any amino acid, and Z=any amino acid except serine or threonine. These inhibitors, which are about 7 to 50 amino acids long, are specific for GSK-3 and strongly inhibit the enzyme with an IC50 of about 150 &mgr;M. Also provided are methods of treating biological conditions mediated by GSK-3 activity, such as potentiating insulin signaling in a subject, treating or preventing type 2 diabetes in a patient, and treating Alzheimer's Disease by administering peptide inhibitors. Compositions of these peptide inhibitors and pharmaceutically acceptable carriers are also provided, as is a method for identifying inhibitors of GSK-3. The invention further relates to a computer-assisted method of structure based drug design of GSK-3 inhibitors using a three-dimensional structure of a peptide substrate of GSK-3.Type: GrantFiled: September 14, 2001Date of Patent: August 24, 2004Assignee: Tel Aviv University Future Technology Development L.P.Inventor: Hagit Eldar-Finkelman
-
Publication number: 20040162234Abstract: Peptide inhibitors of glycogen synthase kinase-3 (GSK-3) having an amino acid sequence motif of XZXXXS(p)X, wherein S(p)=phosphorylated serine or phosphorylated threonine, X=any amino acid, and Z=any amino acid except serine or threonine. These inhibitors, which are about 7 to 20 amino acids long, are specific for GSK-3 and strongly inhibit the enzyme with an IC50 of about 150 &mgr;M. Also provided are methods of treating biological conditions mediated by GSK-3 activity, such as potentiating insulin signaling in a subject, treating or preventing type 2 diabetes in a patient, and treating Alzheimer's Disease by administering peptide inhibitors. Compositions of these peptide inhibitors and pharmaceutically acceptable carriers are also provided, as is a method for identifying inhibitors of GSK-3. The invention further relates to a computer-assisted method of structure based drug design of GSK-3 inhibitors using a three-dimensional structure of a peptide substrate of GSK-3.Type: ApplicationFiled: March 29, 2004Publication date: August 19, 2004Applicant: Tel Aviv University Future Technology Development L.P.Inventor: Hagit Eldar-Finkelman